Skip to content

Advertisement

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.

Human endometrial regenerative cells attenuate renal ischemia reperfusion injury in mice

  • †1, 2,
  • †1,
  • †3,
  • 1, 2,
  • 4,
  • 2,
  • 1,
  • 5, 6 and
  • 1, 2Email author
†Contributed equally
Journal of Translational Medicine201614:28

https://doi.org/10.1186/s12967-016-0782-3

©  Sun et al. 2016

  • Received: 17 October 2015
  • Accepted: 13 January 2016
  • Published:

Abstract

Background

Endometrial regenerative cells (ERCs) is an attractive novel type of adult mesenchymal stem cells that can be non-invasively obtained from menstrual blood and are easily replicated at a large scale without tumorigenesis. We have previously reported that ERCs exhibit unique immunoregulatory properties in experimental studies in vitro and in vivo. In this study, the protective effects of ERCs on renal ischemia–reperfusion injury (IRI) were examined.

Methods

Renal IRI in C57BL/6 mice was induced by clipping bilateral renal pedicles for 30 min, followed by reperfusion for 48 h. ERCs were isolated from healthy female menstrual blood, and were injected (1 million/mouse, i.v.) into mice 2 h prior to IRI induction. Renal function, pathological and immunohistological changes, cell populations and cytokine profiles were evaluated after 48 h of renal reperfusion.

Results

Here, we showed that as compared to untreated controls, administration of ERCs effectively prevented renal damage after IRI, indicated by better renal function and less pathological changes, which were associated with increased serum levels of IL-4, but decreased levels of TNF-α, IFN-γ and IL-6. Also, ERC-treated mice displayed significantly less splenic and renal CD4+ and CD8+ T cell populations, while the percentage of splenic CD4+CD25+ regulatory T cells and infiltrating M2 macrophages in the kidneys were significantly increased in ERC-treated mice.

Conclusions

This study demonstrates that the novel anti-inflammatory and immunoregulatory effects of ERCs are associated with attenuation of renal IRI, suggesting that the unique features of ERCs may make them a promising candidate for cell therapies in the treatment of ischemic acute kidney injury in patients.

Keywords

  • Endometrial regenerative cells
  • Ischemia–reperfusion injury
  • Kidney

Background

Renal ischemia–reperfusion injury (IRI) is a major cause of clinical acute kidney injury (AKI), which is a frequent and serious problem in transplantation, renal surgery, renal diseases and trauma [1]. Vigorous research on IRI has been conducted, but the mortality rate of AKI remains high. There is no effective therapy available to treat renal IRI or ischemic AKI. Thus, new therapeutic approaches are desperately needed.

The underlying mechanisms of renal IRI are complex and multiple factors are involved. The pathophysiology of renal IRI includes initial cellular damage caused by ischemia, as well as delayed renal injury resulting from inflammatory and immune responses following reperfusion [2]. Numerous studies have demonstrated that renal IRI is an inflammatory disease, which is mediated by innate and adoptive immune responses [3–6]. The activation and infiltration of neutrophils [5, 7], macrophages [8], T lymphocytes [9], monocytes and inflammatory mediators are involved in modulating severity of injury in experimental models of renal IRI [10–13]. Animal models have showed that inflammation begins as early as 30 min of reperfusion, and inhibition of the immune response activated by renal IRI dramatically improves renal function and histological integrity after ischemia [14].

In the past few years, stem cell-based therapy as a promising alternative solution draws considerable attention for disease treatment. As a potential candidate for regenerative medicine, mesenchymal stem cells (MSCs) promote tissue repair [15–17]. In the meantime, MSCs have immunomodulatory, anti-inflammatory properties and are immune privileged [18]. These cells can modulate the function of immune cells by both cell-to-cell interaction and soluble factor secretion [19, 20]. MSCs can be obtained from different tissues including bone marrow and adipose tissue. However, the disadvantages of using these sources, such as the requirement of invasive access method and the cause of related complications, limited their clinical use and so on [21, 22].

In 2007, Meng et al. discovered the endometrial regenerative cells (ERCs), a novel type of adult MSCs, which satisfy the traits of MSCs but overcome the disadvantages of other conventional sources and the fear of karyotypic abnormalities during culture and possibility of oncogenesis [22]. We and others have reported that ERCs effectively prevent critical limb ischemia [21], attenuate ulcerative colitis [23], stroke [24] and burn injury [25] in mouse models. Also, it has been found that these human cells were not rejected in a xenogeneic animal model [21]. However, whether ERCs could be feasible to simultaneously suppress inflammatory and immune responses, and repair the damaged tissue following IRI remains unclear. Thus, the aim of this study was to explore the potential role of ERC therapy in prevention of renal IRI.

Methods

Preparation of ERCs for in vivo treatment

ERCs were collected from menstrual blood of women (20–40 years old) after informed consent was obtained. Five milliliters of menstrual blood were collected by urine cup-tubing method in an antibiotic containing solution. Mononuclear cells were separated by standard Ficoll method, and the resultant samples were suspended in Dulbecco’s modified Eagle’s medium (DMEM) high glucose supplemented with 10 % fetal bovine serum (FBS), and split into two 10 cm dishes. After overnight incubation, cultured cells revealed marginal adherence to the tissue culture flask. Cells were cultured with media changing twice a week. At the completion of 2 week culture, an outgrowth of adherent cells with a fibroblast-like morphology was observed [22]. The estimated adherent cell number at the start of culture was approximately 1 × 107 [26].

Animals

Eight-week-old male C57BL/6 mice (Aoyide Co., Tianjin, China) weighing 20–25 g were housed under conventional experimental environment with 12 h light–dark cycle in the Animal Care Facility of Tianjin General Surgery Institute. The mice had a free access to commercial standard mouse diet and water. All experiments were conducted in accordance with the protocols approved by the Animal Care and Use Committee of Tianjin Medical University (China) according to the Chinese Council on Animal Care guidelines.

Experimental groups

The experiment was conducted following the protocol described previously [27]. In brief, to test the efficacy of ERCs in attenuation of kidney IRI, C57BL/6 mice were randomly assigned to three groups (n = 6 per group): (1) sham control group, mice were operated by opening and closing the abdomen, without clipping the renal pedicles; (2) untreated IRI group, through a middle abdomen incision, bilateral renal pedicles were clipped for 30 min, then released [27]; and (3) ERC-treated IRI group, 1 × 106 ERCs were intravenously injected 2 h before clipping bilateral renal pedicles [28]. After reperfusion was confirmed, the abdomen was closed in two layers using standard 6-0 sutures. Mice were maintained by continuous monitoring using a temperature-controlled self-regulated heating system after the completion of surgery. To maintain body fluid balance, 1 mL of warm saline was administered intraperitoneally immediately after operation. The mice were sacrificed 48 h after reperfusion for IRI assessment.

Assessment of renal function

Serum levels of both blood urea nitrogen (BUN) and creatinine (Cr) were measured when the mice were sacrificed 48 h after renal reperfusion using multichannel analyzer in the Tianjin Medical University General Hospital (Tianjin, China) for assessing the renal function.

Histological examination

Kidney tissues from each mouse in each group were fixed by 10 % buffered formalin, and embedded in paraffin. Paraffin sections of kidneys (5 μm) stained with Hematoxylin and eosin (H&E) were used for morphology analysis under light microscopy. A semi-quantitative score of tubular damage including cellular necrosis, loss of brush border, cast formation, vacuolization, and tubule dilation were counted as follows: 0, none; 1, <10 %; 2, 11–25 %; 3, 26–45 %; 4, 46–75 %; and 5, >76 % [29].

Immunohistochemistry

To quantitate the cell infiltration, sections were stained with antibodies (Abcam, http://www.abcam.com/). We performed immunohistochemical staining by using anti-CD3 and anti-Ly6G antibodies for detecting intra-renal cellular infiltration of T cells and neutrophils, respectively. The primary antibody was at a dilution of 1:100. Negative control sections, only stained with secondary antibodies but without primary antibodies, were performed to assess the non-specific staining. The specimens were stained according to the instructions of Strept Avidin–Biotin Complex (SABC) kit. Stained sections were photographed using an Olympus inverted microscope (Olympus Imaging America, Center Valley, PA).

Flow cytometric analysis

Phenotypic analysis of various immune cells was performed using a flow cytometry with staining with antibodies against CD4, CD8, CD25, F4/80 or CD206 (eBiosciences, http://www.ebioscience.com/), according to the manufacturer’s instructions. The percentage of each phenotype of immune cells was analyzed with the corresponding Flowjo software.

ELISA

The levels of TNF-α, IFN-γ, IL-6 or IL-4 in the serum samples taken from mice 48 h after IRI were measured using an ELISA Kit (Biolgend, http://www.biolegend.com/) according to the manufacturer’s instructions.

Statistical analysis

Statistical analysis was performed in SPSS version 17.0 software (SPSS Inc., Chicago, USA) and the experimental data were presented as mean ± standard derivation (SD). The data obtained from sham control group, untreated IRI group and ERC-treated IRI group were compared using one-way analysis of variance (ANOVA) to study the effects of ERC treatment on the renal function, histological scores, cell populations and cytokine profiles for repeated measurements. The case number for each experiment is specified in the corresponding figure. p value (p) < 0.05 was considered statistically significant.

Results

ERCs protected renal function in mice with renal IRI

To determine whether the pre-treatment with ERCs could attenuate renal IRI, we subjected mice to bilateral kidney IRI for 30 min. Then the serum BUN and Cr levels were measured after 48 h of induction of IRI. We found that BUN (Fig. 1a) and Cr (Fig. 1b) levels were markedly reduced by ERC treatment compared with those of untreated mice after IRI (p < 0.05), although the levels of BUN and Cr were slightly higher than those of mice in sham control group (p < 0.05).
Fig. 1
Fig. 1

Infused ERCs improves renal function. Serum samples were collected from mice of the sham, IRI-untreated and ERC-treated groups. In comparison with untreated IRI group, infused ERCs significantly reduced serum levels of a BUN and b Cr. Bar graphs represent mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are representative of three separate experiments performed (*p < 0.05, vs. IRI-untreated group, # p < 0.05, vs. sham group, n = 6)

Treatment with ERCs ameliorated renal pathological damages induced by IRI

H&E staining was performed to assess the renal pathological changes. Representative kidney sections and the renal damage score were shown in Fig. 2. It was found that untreated IRI mice displayed severe tubular damage 48 h after renal IRI, characterized by widespread tubular necrosis, loss of brush border, cast formation, tubular dilatation, expansion of Bowman’s capsule and interstitial edema (Fig. 2a, IRI-untreated). In contrast, the kidneys in ERC-treated mice showed normal histology (Fig. 2a, ERC-treated) at the same time point, which was indistinguishable from that of sham control mice (Fig. 2a, sham). In addition, the histopathological damage scores in ERC-treated group were significantly lower than those of untreated IRI group (p < 0.05), which were comparable to those of sham control group (Fig. 2b).
Fig. 2
Fig. 2

Treatment with ERCs significantly attenuates pathological damage induced by IRI in kidneys. Mouse kidneys were subjected to bilateral renal pedicles clipping for 30 min, then released and followed by 48 h reperfusion. Mice were sacrificed and the kidneys were harvested 48 h after reperfusion. a H&E staining was performed to evaluate renal pathological changes. The representative kidney sections of different groups were displayed. Magnification 100×. b Quantitative assessment of kidney damage was performed as described in the “Methods” section. Bar graphs represent mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are representative of three separate experiments (*p < 0.05, vs. IRI-untreated group, n = 6)

ERCs suppressed intra-renal infiltration of neutrophils and T cells after renal IRI

As shown in Fig. 3, neutrophil and CD3+ T cell infiltrations were markedly increased in untreated IRI group as compared with those of sham control group and ERC-treated group. It was suggested that administration of ERCs suppressed neutrophil and CD3+ T cell infiltration. As a result, histological injury of kidney was attenuated. Moreover, loss of the brush border, cast formation and tubular dilatation in kidneys were also significantly suppressed in ERC-treated mice.
Fig. 3
Fig. 3

Infused ERCs suppress inflammatory cell infiltration in kidneys in response to IRI. The neutrophil and T cell accumulations in the kidney were examined using anti-Ly6G and anti-CD3 staining respectively 48 h after reperfusion following 30 min-ischemia injury. Representative sections of kidneys were obtained from sham control, IRI-untreated, and ERC-treated IRI mice. Magnification 100×

Infused ERCs increased the percentage of CD4+CD25+ T cells in the spleen

The underlying mechanisms of renal IRI are complex, including activation and progression of immune response. Regulatory T cells (Tregs), playing a critical role in suppression of both adaptive and innate immune responses, have been shown to attenuate renal IRI [28, 30]. In this study, we detected and compared splenic Treg population in different groups. There was no significant difference in the number of Tregs between untreated IRI group and sham control group. In contrast, CD4+CD25+ Treg population was significantly increased by ERC treatment in mice with renal IRI (p < 0.05, vs. untreated IRI group and sham control group), indicating the protective role of Tregs in ERC-mediated kidney protection (Fig. 4).
Fig. 4
Fig. 4

Infused ERCs increase the percentage of CD4+CD25+ Tregs in the spleen and contribute to the protection of kidney against IRI. a Flow cytometric analysis of splenic CD4+CD25+ Treg population was performed in the sham, IRI-untreated and ERC-treated groups. b ERC treatment significantly increased the percentage of Tregs in IRI mice compared with those of untreated IRI mice. Bar graphs represent mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are a representative of three separate experiments performed (*p < 0.05, vs. IRI-untreated group, # p < 0.05, vs. sham group, n = 6)

ERCs decreased the percentages of CD4+ and CD8+ T cells in the spleen and kidney after renal IRI

To determine the relationship between the changes of T cell population and ERC-mediated renal protection, we investigated the infiltration of CD4+ and CD8+ T cells in both spleen (Fig. 5a) and kidney (Fig. 5b) by flow cytometry. The percentages of CD4+ and CD8+ T cells were significantly decreased in ERC-treated group compared with those of untreated IRI group in both spleen and kidney (Fig. 5c, p < 0.01), which were, in fact, comparable to the control levels in sham control group.
Fig. 5
Fig. 5

ERCs suppress CD4+ and CD8+ T cell populations in the spleen and kidney. Flow cytometric analysis of CD4+ and CD8+ T cell populations was performed in the a spleen and b kidney of the sham, IRI-untreated and ERC-treated groups. c Treatment with ERCs significantly decreased the percentages of CD4+ and CD8+ T cells in the spleen and kidney. Bar graphs represent mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are a representative of three separate experiments performed (*p < 0.01, vs. IRI-untreated group, n = 6)

ERCs suppressed the percentage of total macrophages, but increased M2 macrophages in the kidneys with attenuated IRI

To determine whether the macrophage profile was associated with ERC-mediated attenuation of IRI, we measured total macrophage stained by anti-F4/80 mAb, and M2 macrophages stained by anti-F4/80 and CD206 mAbs by flow cytometry. We found that ERCs effectively suppressed the percentage of total macrophages compared with those of untreated IRI group (p < 0.05), even though slightly higher than those of mice in sham control group (p < 0.05) (Fig. 6a). Interestingly, M2 macrophage population was significantly increased in ERC-treated mice compared to that of untreated IRI mice (p < 0.05). In fact, the percentage of M2 macrophages was undistinguishable between mice in sham control group and ERC-treated IRI group (Fig. 6b).
Fig. 6
Fig. 6

ERCs decrease the percentage of total macrophages but increase M2 macrophages in the kidneys with IRI. Flow cytometric analysis of a F4/80+ total macrophages and b CD206+ M2 macrophages was performed in the kidneys of different groups. In Fig. 6a, vertical axis: FSC-H, horizontal axis: F4/80. Bar graphs represent mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are a representative of three separate experiments performed (*p < 0.05, vs. IRI-untreated group, # p < 0.05, vs. sham group, n = 6)

ERCs attenuated kidney IRI by regulating cytokine expression

The serum levels of pro-inflammatory and anti-inflammatory cytokines were analyzed and compared among different groups. As shown in Fig. 7, the serum levels of pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) were markedly increased in untreated IRI group, whereas ERC treatment significantly reduced the pro-inflammatory cytokine levels in the sera (p < 0.05, ERC-treated group vs. untreated group), even though slightly higher than the baseline serum levels in sham control group (p < 0.05). Meanwhile, treatment with ERCs increased the level of the anti-inflammatory cytokine IL-4 in the sera (p < 0.05), which was even higher than that in sham control mice (p < 0.05). These data suggest that ERCs not only suppress the expression of pro-inflammatory cytokines, but also enhance the level of anti-inflammatory cytokines.
Fig. 7
Fig. 7

ERCs attenuate renal IRI by regulating cytokine levels. Serum samples were collected from the sham, IRI-untreated and ERC-treated groups. Serum levels of TNF-α, IFN-γ, IL-6 and IL-4 were examined by ELISA. Bar graphs represent mean ± SD of three separate experiments. p values were determined by one-way ANOVA. Data shown are a representative of three separate experiments performed (*p < 0.05, vs. IRI-untreated group, # p < 0.05, vs. sham group, n = 6)

Discussion

As we all know, cell therapy has been reported to be an effective method in the treatment of some diseases. ERCs are an attractive novel type of adult MSCs, which can be obtained from menstrual blood. In the current study, we focused on their anti-inflammatory and immunomodulatory properties in attenuation of renal IRI. So we intravenously injected ERCs into mice suffering from renal IRI, an experimental model of ischemic AKI. We have highlighted several findings in this study. First, intravenously injected ERCs decreased intra-renal CD3+ T cell and neutrophil infiltration; second, ERCs increased the percentage of splenic Tregs in mice with attenuated renal damage; third, ERCs decreased CD4+ and CD8+ T cell population in both spleen and kidney; fourth, ERCs down-regulated the percentage of total macrophages, but increased M2 macrophages; finally, injected ERCs suppressed pro-inflammatory cytokines and enhanced anti-inflammatory cytokine expression in mice with ameliorated renal function. To exclude if the therapeutic potential of ERCs is only mediated by cellular component, peripheral blood monocytes were also used as the cell treatment control. As expected, no therapeutic effects were observed according to the assessment of renal function and pathological study (data not shown).

ERCs, an attractive novel type of adult MSCs isolated from menstrual blood, were capable of differentiating into 9 lineages [22]. As we all know, MSCs are a group of self-renewing, pluripotent stromal cells derived from tissues such as bone marrow [31], cord blood [32], adipose tissue [33] and amniotic fluid [34], and have been demonstrated that they could promote tissue repair and possess immunomodulatory and anti-inflammatory properties. ERCs express CD9, CD13, CD14, CD29, CD44, CD73, CD90, CD105, CD117, CD133, CD146 [35], but not STRO-1, CD31 (endothelial) and CD34 (haemopoietic stem cell and endothelial) [36]. The human endometrium has unique immunological requirements in nature. For example, in pregnancy, the endometrium must tolerate invading embryo, which expresses both paternal and maternal antigens. A study demonstrated that endometrial MSCs were able to suppress neural inflammation in a mouse model of multiple sclerosis [37]. MSCs have been demonstrated to inhibit ongoing mixed lymphocyte reaction (MLR) [38], induce generation of regulatory T cells [39], and in vivo suppress autoimmunity such as collagen induced arthritis [40]. But the application of these cell types is limited by availability, invasiveness of extraction and in some cases by proliferative capacity [22]. ERCs are a new type of MSCs, which have some advantages compared with many conventional sources of MSCs. ERCs can be easily expanded and used for females as a non-invasively obtained and ethically appropriate autologous stem cell alternative [22]. We previously reported the role of ERCs in limb ischemia injury [21], UC [23] and recently in prevention of transplant rejection (unpublished data). However the role of ERCs in attenuation of IRI in kidney has not been tested.

The underlying mechanisms of renal IRI are complex, including activation and progression of the immune response [41]. Tregs play a critical role in suppression of both innate and adaptive immune responses [30]. CD4+CD25+ Tregs account for 5–10 % of the CD4+ T cell panel in healthy human and mice, which are sufficient to play an important role in the maintenance of immune homeostasis and the limitation of autoimmune disease [42]. In several studies, the investigators used PC61, an anti-CD25 monoclonal antibody to deplete Tregs before renal ischemia to confirm the protective effect of the Tregs; depletion of Tregs leads to deterioration of the renal IRI compared to those of mice that only suffered from renal IRI and had no other treatment [28, 43, 44]. In another study, the researchers used depletion and adoptive transfer strategy to determine the function of Tregs in the renal IRI model. Administration of anti-CD25 mAb significantly decreased the number of splenic Tregs [28, 45]. In addition, they observed that the adoptive transfer of Tregs back into Treg-depleted mice partially restored the protective effect of ischemic preconditioning [46–48]. Finally, partial depletion and adoptive transfer of Tregs partially mitigated or restored the renal injury [43, 49]. Blocking Tregs worsens AKI and infusion of Tregs protects organs against AKI induced by IRI [46, 50] and cisplatin [51], respectively. Collectively, these data suggested that Treg induction was one of the underlying mechanisms against renal IRI. In current study, we did not find statistically significant difference in the percentage of Tregs between sham control group and untreated IRI group, but observed that Tregs were significantly increased by ERC treatment, even higher than that of sham control group. Thus, it indicated that ERC could increase Tregs which may be related to the suppression of immune response and inflammatory reaction. As a result, intravenous injection of ERCs attenuated renal damage induced by IRI.

To investigate the effects of ERCs on different T lymphocyte subsets, we have also measured the levels of CD4+ and CD8+ T cells in different groups. Some studies have reported the effects of CD4+ and CD8+ T cells in renal IRI. In renal IRI, CD4 and CD8 double knockout mice demonstrated significant functional protection [52]. A more direct proof of the role of T cells in IRI has been demonstrated in a mouse liver injury model that a marked protection of liver function was found in T cell-deficient athymic mice [53]. T cell-deficient mice could attenuate renal IRI, and T cell adoptive transfer into these mice restored the injury. Again CD4 knockout mice showed marked protection from renal IRI compared with wild-type mice and adoptive transfer of wild-type CD4+ cells into these CD4 knockout mice resulted in a worsening injury [9]. In current study, as compared with untreated IRI group, CD4+ and CD8+ T cells were significantly reduced after ERC treatment, indicating that ERCs may reduce T cell accumulation. The results suggested that ERCs may have regulatory functions on the cell populations of splenic CD4+ and CD8+ T cells. All the studies have demonstrated the critical role of CD4+ and CD8+ T cells in renal IRI.

Macrophages, belonging to the mononuclear phagocyte system, are potent immune regulators which play an important role in tissue homeostasis and remodeling [4, 54–56]. It has been reported that ablation of macrophages by some different strategies 48–72 h after IRI could inhibit tubular repair and enhance injury [57–59]. In another study, adoptive transfer of resting RAW 264.7 macrophages (a mouse leukemic monocyte cell line) in macrophage-depleted mice after IRI could attenuate ischemic AKI and promote kidney repair [53, 60]. Meanwhile, macrophage-cell-based therapy can limit tubular injury and promote renal repair [61]. Accordingly, macrophages show different functions and phenotypes in response to local metabolic and immune microenvironment [62]. In general, there are two broad but distinct subsets of macrophages that are categorized as either classically activated (M1) or alternatively activated (M2) [63, 64]. Recent studies have demonstrated that macrophages are key cells in both the initiation and resolution of renal injury [65–67]. In current study, ERC treatment induced the subset of M2 cells, which may play an important role in attenuation of renal IRI. This is consistent with previous finding that protection of the kidney against ischemia–reperfusion injury and suppression of inflammation could be mediated by inducing M2 polarization [66], as well as the HO-1 expression promotes a “regulatory” M2 phenotype with the large augmentation in IL-10 production [68]. Several studies also have found that the different macrophage subset populations can be recruited and/or activated during different phases of ischemic injury and repair [56, 59, 69]. However, the mechanism of phenotype switching from pro-inflammatory to anti-inflammatory state is not fully understood in damaged kidney caused by IRI. Further studies to dissect these issues are warranted.

In this study, we have also assessed renal inflammatory cytokines 48 h after renal IRI. It is well known that inflammation is induced by IRI, typically occurs in the absence of microorganisms, and has been termed as sterile inflammation [70]. Similar to the response to invading pathogens, the sterile inflammation induced by IRI can also lead to the marked recruitment of neutrophils and the production of cytokines [70]. Neutrophils and macrophages were the initial infiltrates in the injury phase of renal IRI. Similarly, based on our data, IRI also increased the influx of macrophages and neutrophils, but ERCs reduced the influx of those cells during the post-ischemic period. On the other hand, cytokines may play important roles in IRI. Although there is extensive literature regarding the function of cytokines in post-ischemic tissue injury, we only focused on TNF-α, IFN-γ, IL-6 and IL-4 in this study. As assessed by ELISA, the pro-inflammatory cytokines, such as TNF-α, IFN-γ and IL-6, were obviously higher in the untreated IRI group than those of sham group. Once released, they bind with specific receptors to induce the expression of chemokines. These activities promote the recruitment and activation of neutrophils in post-ischemic tissues. Finally, they affected the outcome of the renal IRI.

Concerning the source of ERCs, it has been found that endometrial MSCs’ perivascular location in both the basal and functional layers, indicating that they will be shed each month during menstruation [71]. To date, the source of endometrial MSCs is not yet clear. It is claimed that endometrial MSCs originate from resident stem/progenitor cells. A further study of the specific characterization of ERCs and the mechanisms of ERC-mediated protection in IRI is still underway.

Conclusions

Our data suggest that ERC treatment is able to protect kidneys against IRI, by significantly decreasing histological damage,inflammatory infiltration, pro-inflammatory cytokine expression, as well as up-regulating Tregs, M2 macrophages and anti-inflammatory cytokines. Therefore, ERCs might provide a novel and potent therapeutic option to prevent renal IRI. The clinical availability of ERCs might further facilitate rapid clinical translation of the present findings in this study.

Notes

Abbreviations

ERC: 

endometrial regenerative cells

IRI: 

ischemia–reperfusion injury

Treg: 

regulatory T cell

MSC: 

mesenchymal stem cells

TNF: 

tumor necrosis factor

IL: 

interleukin

Declarations

Authors’ contributions

PS, JL and WWL carried out the research, analyzed the data and drafted the manuscript. XX, HL, and HH analyzed the data. CD participated in the design of the study and revised the manuscript. HW conceived of the study, participated in its design and coordination, and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by grants to H.W. from National Natural Science Foundation of China (No. 81273257 and 81471584), Tianjin Application Basis and Cutting-Edge Technology Research Grant (14JCZDJC35700), and Li Jieshou Intestinal Barrier Research Special Fund (LJS-201412). The authors are grateful to Dr. Tao Shi for his technical support and review of pathological slides.

Competing interests

All authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of General Surgery, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin, 300052, China
(2)
Tianjin General Surgery Institute, Tianjin, China
(3)
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China
(4)
Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China
(5)
Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada
(6)
Immunity and Infection Research Centre, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada

References

  1. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, Cosio FG. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527–35.PubMedView ArticleGoogle Scholar
  2. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 2004;66:480–5.PubMedView ArticleGoogle Scholar
  3. Kinsey GR, Li L, Okusa MD. Inflammation in acute kidney injury. Nephron Exp Nephrol. 2008;109:e102–7.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant. 2006;21:1231–9.PubMedView ArticleGoogle Scholar
  5. Ranganathan PV, Jayakumar C, Mohamed R, Dong Z, Ramesh G. Netrin-1 regulates the inflammatory response of neutrophils and macrophages, and suppresses ischemic acute kidney injury by inhibiting COX-2-mediated PGE2 production. Kidney Int. 2013;83:1087–98.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Jones DR, Lee HT. Protecting the kidney during critical illness. Curr Opin Anaesthesiol. 2007;20:106–12.PubMedView ArticleGoogle Scholar
  7. Miura M, Fu X, Zhang QW, Remick DG, Fairchild RL. Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am J Pathol. 2001;159:2137–45.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Day YJ, Huang L, Ye H, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol. 2005;288:F722–31.PubMedView ArticleGoogle Scholar
  9. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O’Donnell MP, Rabb H. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest. 2001;108:1283–90.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strieter RM, Rosin DL, Okusa MD. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010;120:331–42.PubMedPubMed CentralView ArticleGoogle Scholar
  11. Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol. 2010;30:268–77.PubMedPubMed CentralView ArticleGoogle Scholar
  12. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol. 2009;130:41–50.PubMedPubMed CentralView ArticleGoogle Scholar
  13. Ferenbach DA, Sheldrake TA, Dhaliwal K, Kipari TM, Marson LP, Kluth DC, Hughes J. Macrophage/monocyte depletion by clodronate, but not diphtheria toxin, improves renal ischemia/reperfusion injury in mice. Kidney Int. 2012;82:928–33.PubMedView ArticleGoogle Scholar
  14. Lai LW, Yong KC, Igarashi S, Lien YH. A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia-reperfusion injury. Kidney Int. 2007;71:1223–31.PubMedView ArticleGoogle Scholar
  15. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25:2648–59.PubMedView ArticleGoogle Scholar
  16. Imanishi Y, Saito A, Komoda H, Kitagawa-Sakakida S, Miyagawa S, Kondoh H, Ichikawa H, Sawa Y. Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol. 2008;44:662–71.PubMedView ArticleGoogle Scholar
  17. de Vries DK, Schaapherder AF, Reinders ME. Mesenchymal stromal cells in renal ischemia/reperfusion injury. Front Immunol. 2012;3:162.PubMedPubMed CentralView ArticleGoogle Scholar
  18. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12:574–91.PubMedView ArticleGoogle Scholar
  19. He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci. 2012;57:3136–44.PubMedView ArticleGoogle Scholar
  20. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67:1–8.PubMedView ArticleGoogle Scholar
  21. Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau AM, Pyszniak A, Carrier E, Ichim TE, Riordan NH. Allogeneic endometrial regenerative cells: an “Off the shelf solution” for critical limb ischemia? J Transl Med. 2008;6:45.PubMedPubMed CentralView ArticleGoogle Scholar
  22. Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, Wang H, Ge W, Bogin V, Chan KW, Thebaud B, Riordan NH. Endometrial regenerative cells: a novel stem cell population. J Transl Med. 2007;5:57.PubMedPubMed CentralView ArticleGoogle Scholar
  23. Lv Y, Xu X, Zhang B, Zhou G, Li H, Du C, Han H, Wang H. Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice. J Transl Med. 2014;12:344.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Borlongan CV, Kaneko Y, Maki M, Yu SJ, Ali M, Allickson JG, Sanberg CD, Kuzmin-Nichols N, Sanberg PR. Menstrual blood cells display stem cell-like phenotypic markers and exert neuroprotection following transplantation in experimental stroke. Stem Cells Dev. 2010;19:439–52.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Drago H, Marin GH, Sturla F, Roque G, Martire K, Diaz Aquino V, Lamonega R, Gardiner C, Ichim T, Riordan N, Raimondi JC, Bossi S, Samadikuchaksaraei A, van Leeuwen M, Tau JM, Nunez L, Larsen G, Spretz R, Mansilla E. The next generation of burns treatment: intelligent films and matrix, controlled enzymatic debridement, and adult stem cells. Transplant Proc. 2010;42:345–9.PubMedView ArticleGoogle Scholar
  26. Hida N, Nishiyama N, Miyoshi S, Kira S, Segawa K, Uyama T, Mori T, Miyado K, Ikegami Y, Cui C, Kiyono T, Kyo S, Shimizu T, Okano T, Sakamoto M, Ogawa S, Umezawa A. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells. 2008;26:1695–704.PubMedView ArticleGoogle Scholar
  27. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117:2847–59.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Hu J, Zhang L, Wang N, Ding R, Cui S, Zhu F, Xie Y, Sun X, Wu D, Hong Q, Li Q, Shi S, Liu X, Chen X. Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int. 2013;84:521–31.PubMedPubMed CentralView ArticleGoogle Scholar
  29. Wang W, Faubel S, Ljubanovic D, Mitra A, Falk SA, Kim J, Tao Y, Soloviev A, Reznikov LL, Dinarello CA, Schrier RW, Edelstein CL. Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal Physiol. 2005;288:F997–1004.PubMedView ArticleGoogle Scholar
  30. Lee VW, Wang YM, Wang YP, Zheng D, Polhill T, Cao Q, Wu H, Alexander IE, Alexander SI, Harris DC. Regulatory immune cells in kidney disease. Am J Physiol Renal Physiol. 2008;295:F335–42.PubMedView ArticleGoogle Scholar
  31. Edwards RG. Stem cells today: B1. Bone marrow stem cells. Reprod Biomed Online. 2004;9:541–83.PubMedView ArticleGoogle Scholar
  32. Harris DT, Badowski M, Ahmad N, Gaballa MA. The potential of cord blood stem cells for use in regenerative medicine. Expert Opin Biol Ther. 2007;7:1311–22.PubMedView ArticleGoogle Scholar
  33. Parker AM, Katz AJ. Adipose-derived stem cells for the regeneration of damaged tissues. Expert Opin Biol Ther. 2006;6:567–78.PubMedView ArticleGoogle Scholar
  34. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol. 2007;25:100–6.PubMedView ArticleGoogle Scholar
  35. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.PubMedView ArticleGoogle Scholar
  36. Dimitrov R, Timeva T, Kyurkchiev D, Stamenova M, Shterev A, Kostova P, Zlatkov V, Kehayov I, Kyurkchiev S. Characterization of clonogenic stromal cells isolated from human endometrium. Reproduction. 2008;135:551–8.PubMedView ArticleGoogle Scholar
  37. Peron JP, Jazedje T, Brandao WN, Perin PM, Maluf M, Evangelista LP, Halpern S, Nisenbaum MG, Czeresnia CE, Zatz M, Camara NO, Rizzo LV. Human endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous system of EAE mice. Stem Cell Rev. 2012;8:940–52.PubMedView ArticleGoogle Scholar
  38. Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Zhao RC. Allogeneic bone marrow-derived flk-1 + Sca-1- mesenchymal stem cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol. 2004;32:861–7.PubMedView ArticleGoogle Scholar
  39. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4 + or CD8 + regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92:881–8.PubMedView ArticleGoogle Scholar
  40. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007;56:1175–86.PubMedView ArticleGoogle Scholar
  41. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826–37.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology. 2012;136:115–22.PubMedPubMed CentralView ArticleGoogle Scholar
  43. Lai LW, Yong KC, Lien YH. Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury. Kidney Int. 2012;81:983–92.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Rabb H, Ramirez G, Saba SR, Reynolds D, Xu J, Flavell R, Antonia S. Renal ischemic-reperfusion injury in L-selectin-deficient mice. Am J Physiol. 1996;271:F408–13.PubMedGoogle Scholar
  45. Jun C, Ke W, Qingshu L, Ping L, Jun D, Jie L, Bo C, Su M. Protective effect of CD4(+)CD25(high)CD127(low) regulatory T cells in renal ischemia-reperfusion injury. Cell Immunol. 2014;289:106–11.PubMedView ArticleGoogle Scholar
  46. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H, Ju ST, Okusa MD. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol. 2009;20:1744–53.PubMedPubMed CentralView ArticleGoogle Scholar
  47. Lee H, Nho D, Chung HS, Lee H, Shin MK, Kim SH, Bae H. CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. Kidney Int. 2010;78:1100–9.PubMedView ArticleGoogle Scholar
  48. Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, Lobo PI, Okusa MD. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol. 2012;23:1528–37.PubMedPubMed CentralView ArticleGoogle Scholar
  49. Cho WY, Choi HM, Lee SY, Kim MG, Kim HK, Jo SK. The role of Tregs and CD11c(+) macrophages/dendritic cells in ischemic preconditioning of the kidney. Kidney Int. 2010;78:981–92.PubMedView ArticleGoogle Scholar
  50. Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int. 2010;77:771–80.PubMedPubMed CentralView ArticleGoogle Scholar
  51. Yoshida T, Kurella M, Beato F, Min H, Ingelfinger JR, Stears RL, Swinford RD, Gullans SR, Tang SS. Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int. 2002;61:1646–54.PubMedView ArticleGoogle Scholar
  52. Rabb H, Daniels F, O’Donnell M, Haq M, Saba SR, Keane W, Tang WW. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol. 2000;279:F525–31.PubMedGoogle Scholar
  53. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, Engelhardt JF. CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest. 1997;100:279–89.PubMedPubMed CentralView ArticleGoogle Scholar
  54. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant. 2008;23:842–52.PubMedView ArticleGoogle Scholar
  55. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–55.PubMedPubMed CentralView ArticleGoogle Scholar
  56. Filardy AA, Pires DR, Nunes MP, Takiya CM, Freire-de-Lima CG, Ribeiro-Gomes FL, DosReis GA. Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in macrophages. J Immunol. 2010;185:2044–50.PubMedView ArticleGoogle Scholar
  57. Jang HS, Kim J, Park YK, Park KM. Infiltrated macrophages contribute to recovery after ischemic injury but not to ischemic preconditioning in kidneys. Transplantation. 2008;85:447–55.PubMedView ArticleGoogle Scholar
  58. Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT, Pei H, Chen L, Zheng JJ, Carroll TJ, Pollard JW, McMahon AP, Lang RA, Duffield JS. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci USA. 2010;107:4194–9.PubMedPubMed CentralView ArticleGoogle Scholar
  59. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C, Cantley LG. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22:317–26.PubMedPubMed CentralView ArticleGoogle Scholar
  60. Jung M, Sola A, Hughes J, Kluth DC, Vinuesa E, Vinas JL, Perez-Ladaga A, Hotter G. Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. Kidney Int. 2012;81:969–82.PubMedView ArticleGoogle Scholar
  61. Vinuesa E, Hotter G, Jung M, Herrero-Fresneda I, Torras J, Sola A. Macrophage involvement in the kidney repair phase after ischaemia/reperfusion injury. J Pathol. 2008;214:104–13.PubMedView ArticleGoogle Scholar
  62. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–64.PubMedView ArticleGoogle Scholar
  63. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.PubMedView ArticleGoogle Scholar
  64. Wang Y, Harris DC. Macrophages in renal disease. J Am Soc Nephrol. 2011;22:21–7.PubMedView ArticleGoogle Scholar
  65. Kluth DC, Erwig LP, Rees AJ. Multiple facets of macrophages in renal injury. Kidney Int. 2004;66:542–57.PubMedView ArticleGoogle Scholar
  66. Ranganathan PV, Jayakumar C, Ramesh G. Netrin-1-treated macrophages protect the kidney against ischemia-reperfusion injury and suppress inflammation by inducing M2 polarization. Am J Physiol Renal Physiol. 2013;304:F948–57.PubMedPubMed CentralView ArticleGoogle Scholar
  67. Huen SC, Cantley LG. Macrophage-mediated injury and repair after ischemic kidney injury. Pediatr Nephrol. 2015;30:199–209.PubMedView ArticleGoogle Scholar
  68. Ferenbach DA, Ramdas V, Spencer N, Marson L, Anegon I, Hughes J, Kluth DC. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol Ther. 2010;18:1706–13.PubMedPubMed CentralView ArticleGoogle Scholar
  69. Alikhan MA, Jones CV, Williams TM, Beckhouse AG, Fletcher AL, Kett MM, Sakkal S, Samuel CS, Ramsay RG, Deane JA, Wells CA, Little MH, Hume DA, Ricardo SD. Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses. Am J Pathol. 2011;179:1243–56.PubMedPubMed CentralView ArticleGoogle Scholar
  70. Kvietys PR, Granger DN. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med. 2012;52:556–92.PubMedPubMed CentralView ArticleGoogle Scholar
  71. Ulrich D, Muralitharan R, Gargett CE. Toward the use of endometrial and menstrual blood mesenchymal stem cells for cell-based therapies. Expert Opin Biol Ther. 2013;13:1387–400.PubMedView ArticleGoogle Scholar

Copyright

© Sun et al. 2016

Advertisement

Journal of Translational Medicine

ISSN: 1479-5876

Contact us